|
Pioneering a new era of in vivo imaging. |
Acquired |
2005 |
View Profile |
|
Developing resolvins, a novel class of therapies to treat inflammatory diseases and their complications. |
Private |
2005 |
View Profile |
|
Software to enable applications transparent use of cluster supercomputers |
Acquired |
2005 |
View Profile |
|
Developing a software platform to support the emerging interventional oncology market. |
Private |
2005 |
View Profile |
|
Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. |
Private |
2006 |
View Profile |
|
Disrupting the landscape of clinical diagnostics with T2MR. |
Private |
2006 |
View Profile |
|
Developing biologics to target autoimmune/inflammatory diseases. |
Private |
2006 |
View Profile |
|
Developing innovative technology for the low-cost conversion of abundant biomass. |
Private |
2006 |
View Profile |
|
Creating novel antibiotics for serious and life-threatening multi-drug resistant infections. |
Public |
2006 |
View Profile |
|
Discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. |
Private |
2007 |
View Profile |
|
Capitalizing on the global abundance of waste CO2 to economically produce renewable fuels and chemicals. |
Private |
2007 |
View Profile |
|
Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. |
Private |
2007 |
View Profile |
|
Developing a new class of highly selective targeted and programmable therapeutics called Accurins™. |
Private |
2007 |
View Profile |
|
Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. |
Private |
2007 |
View Profile |
|
Developing ground-breaking tools in high definition diagnostics. |
Private |
2007 |
View Profile |
|
Platform technology enabling novel therapies for treatment of sleep disorders |
Acquired |
2007 |
View Profile |
|
Developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. |
Private |
2008 |
View Profile |
|
|
Private |
2008 |
View Profile |
|
Developing and manufacturing revolutionary, low-cost, high-performance flow cytometers for researchers. |
Acquired |
2008 |
View Profile |
|
Developing a pipeline of innovative treatments for bladder diseases. |
Private |
2008 |
View Profile |